Résultats à un an de l'efficacité et de l'innocuité du MicroShunt InnFocus selon l'emplacement et la concentration de MMC

Translated title of the contribution: One-year results on the safety and efficacy of the InnFocus MicroShunt depending on placement and concentration of mitomycin C

I. Riss, J. Batlle, L. Pinchuk, Y. P. Kato, B. A. Weber, Jean-Marie A Parel

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose. - To compare intraocular pressure (IOP) at one year with the InnFocus MicroShunt®with or without cataract surgery with according to placement and concentration of mitomycin C(MMC) Design. - A retrospective two-center, two-surgeon study (France and Dominican Republic).Patients and methods. - Adults with POAG requiring filtering surgery. One MicroShunt®wasplaced in one eye of each patient. The effect of concentration and site of application of MMCwas assessed by IOP and medication reduction at one year.Results. - Eighty-seven eyes were studied with one-year follow-up. Twenty-three eyes treatedwith 0.4 mg/mL MMC close to the limbus demonstrated a 55% reduction in IOP from 23.8 ± 5.3at baseline to 10.7 ± 2.8 mmHg at one year. Topical glaucoma medication/patient was reduced85% from 2.4 ± 0.9 to 0.3 ± 0.8. Thirty-one eyes treated with 0.2 mg/mL MMC close to the limbusdemonstrated a 52% reduction in IOP from 27.9 ± 6.7 at baseline to 13.3 ± 3.3 mmHg at one year.Topical glaucoma medication/patient was reduced 88% from 2.5 ± 1.4 to 0.5 ± 1.0. Thirty-threeeyes treated with 0.4 mg/mL MMC deep in the pocket demonstrated a 38% reduction in IOP from25.4 ± 7.9 at baseline to 15.7 ± 4.6 mmHg at one year. Topical glaucoma medication/patient wasreduced 72% from 2.9 ± 1.0 to 0.8 ± 1.3. There were no sight-threatening long-term adverseevents.Conclusion. - The InnFocus MicroShunt®is a filtering surgery whose efficacy is related to thelocation of application and concentration of MMC used.

Original languageFrench
Pages (from-to)855-860
Number of pages6
JournalJournal Francais d'Ophtalmologie
Volume38
Issue number9
DOIs
StatePublished - Nov 1 2015

Fingerprint

Mitomycin
Intraocular Pressure
Safety
Glaucoma
Filtering Surgery
Dominican Republic
Cataract
France

Keywords

  • Filtering surgery
  • Glaucoma surgery
  • MicroShunt®
  • Minimally invasivesurgery for glaucoma

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Résultats à un an de l'efficacité et de l'innocuité du MicroShunt InnFocus selon l'emplacement et la concentration de MMC. / Riss, I.; Batlle, J.; Pinchuk, L.; Kato, Y. P.; Weber, B. A.; Parel, Jean-Marie A.

In: Journal Francais d'Ophtalmologie, Vol. 38, No. 9, 01.11.2015, p. 855-860.

Research output: Contribution to journalArticle

@article{ffcc2f5b825a45a491c62da13088aa30,
title = "R{\'e}sultats {\`a} un an de l'efficacit{\'e} et de l'innocuit{\'e} du MicroShunt InnFocus selon l'emplacement et la concentration de MMC",
abstract = "Purpose. - To compare intraocular pressure (IOP) at one year with the InnFocus MicroShunt{\circledR}with or without cataract surgery with according to placement and concentration of mitomycin C(MMC) Design. - A retrospective two-center, two-surgeon study (France and Dominican Republic).Patients and methods. - Adults with POAG requiring filtering surgery. One MicroShunt{\circledR}wasplaced in one eye of each patient. The effect of concentration and site of application of MMCwas assessed by IOP and medication reduction at one year.Results. - Eighty-seven eyes were studied with one-year follow-up. Twenty-three eyes treatedwith 0.4 mg/mL MMC close to the limbus demonstrated a 55{\%} reduction in IOP from 23.8 ± 5.3at baseline to 10.7 ± 2.8 mmHg at one year. Topical glaucoma medication/patient was reduced85{\%} from 2.4 ± 0.9 to 0.3 ± 0.8. Thirty-one eyes treated with 0.2 mg/mL MMC close to the limbusdemonstrated a 52{\%} reduction in IOP from 27.9 ± 6.7 at baseline to 13.3 ± 3.3 mmHg at one year.Topical glaucoma medication/patient was reduced 88{\%} from 2.5 ± 1.4 to 0.5 ± 1.0. Thirty-threeeyes treated with 0.4 mg/mL MMC deep in the pocket demonstrated a 38{\%} reduction in IOP from25.4 ± 7.9 at baseline to 15.7 ± 4.6 mmHg at one year. Topical glaucoma medication/patient wasreduced 72{\%} from 2.9 ± 1.0 to 0.8 ± 1.3. There were no sight-threatening long-term adverseevents.Conclusion. - The InnFocus MicroShunt{\circledR}is a filtering surgery whose efficacy is related to thelocation of application and concentration of MMC used.",
keywords = "Filtering surgery, Glaucoma surgery, MicroShunt{\circledR}, Minimally invasivesurgery for glaucoma",
author = "I. Riss and J. Batlle and L. Pinchuk and Kato, {Y. P.} and Weber, {B. A.} and Parel, {Jean-Marie A}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.jfo.2015.05.005",
language = "French",
volume = "38",
pages = "855--860",
journal = "Journal Francais d'Ophtalmologie",
issn = "0181-5512",
publisher = "Elsevier Masson",
number = "9",

}

TY - JOUR

T1 - Résultats à un an de l'efficacité et de l'innocuité du MicroShunt InnFocus selon l'emplacement et la concentration de MMC

AU - Riss, I.

AU - Batlle, J.

AU - Pinchuk, L.

AU - Kato, Y. P.

AU - Weber, B. A.

AU - Parel, Jean-Marie A

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Purpose. - To compare intraocular pressure (IOP) at one year with the InnFocus MicroShunt®with or without cataract surgery with according to placement and concentration of mitomycin C(MMC) Design. - A retrospective two-center, two-surgeon study (France and Dominican Republic).Patients and methods. - Adults with POAG requiring filtering surgery. One MicroShunt®wasplaced in one eye of each patient. The effect of concentration and site of application of MMCwas assessed by IOP and medication reduction at one year.Results. - Eighty-seven eyes were studied with one-year follow-up. Twenty-three eyes treatedwith 0.4 mg/mL MMC close to the limbus demonstrated a 55% reduction in IOP from 23.8 ± 5.3at baseline to 10.7 ± 2.8 mmHg at one year. Topical glaucoma medication/patient was reduced85% from 2.4 ± 0.9 to 0.3 ± 0.8. Thirty-one eyes treated with 0.2 mg/mL MMC close to the limbusdemonstrated a 52% reduction in IOP from 27.9 ± 6.7 at baseline to 13.3 ± 3.3 mmHg at one year.Topical glaucoma medication/patient was reduced 88% from 2.5 ± 1.4 to 0.5 ± 1.0. Thirty-threeeyes treated with 0.4 mg/mL MMC deep in the pocket demonstrated a 38% reduction in IOP from25.4 ± 7.9 at baseline to 15.7 ± 4.6 mmHg at one year. Topical glaucoma medication/patient wasreduced 72% from 2.9 ± 1.0 to 0.8 ± 1.3. There were no sight-threatening long-term adverseevents.Conclusion. - The InnFocus MicroShunt®is a filtering surgery whose efficacy is related to thelocation of application and concentration of MMC used.

AB - Purpose. - To compare intraocular pressure (IOP) at one year with the InnFocus MicroShunt®with or without cataract surgery with according to placement and concentration of mitomycin C(MMC) Design. - A retrospective two-center, two-surgeon study (France and Dominican Republic).Patients and methods. - Adults with POAG requiring filtering surgery. One MicroShunt®wasplaced in one eye of each patient. The effect of concentration and site of application of MMCwas assessed by IOP and medication reduction at one year.Results. - Eighty-seven eyes were studied with one-year follow-up. Twenty-three eyes treatedwith 0.4 mg/mL MMC close to the limbus demonstrated a 55% reduction in IOP from 23.8 ± 5.3at baseline to 10.7 ± 2.8 mmHg at one year. Topical glaucoma medication/patient was reduced85% from 2.4 ± 0.9 to 0.3 ± 0.8. Thirty-one eyes treated with 0.2 mg/mL MMC close to the limbusdemonstrated a 52% reduction in IOP from 27.9 ± 6.7 at baseline to 13.3 ± 3.3 mmHg at one year.Topical glaucoma medication/patient was reduced 88% from 2.5 ± 1.4 to 0.5 ± 1.0. Thirty-threeeyes treated with 0.4 mg/mL MMC deep in the pocket demonstrated a 38% reduction in IOP from25.4 ± 7.9 at baseline to 15.7 ± 4.6 mmHg at one year. Topical glaucoma medication/patient wasreduced 72% from 2.9 ± 1.0 to 0.8 ± 1.3. There were no sight-threatening long-term adverseevents.Conclusion. - The InnFocus MicroShunt®is a filtering surgery whose efficacy is related to thelocation of application and concentration of MMC used.

KW - Filtering surgery

KW - Glaucoma surgery

KW - MicroShunt®

KW - Minimally invasivesurgery for glaucoma

UR - http://www.scopus.com/inward/record.url?scp=84948580802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948580802&partnerID=8YFLogxK

U2 - 10.1016/j.jfo.2015.05.005

DO - 10.1016/j.jfo.2015.05.005

M3 - Article

C2 - 26363923

AN - SCOPUS:84948580802

VL - 38

SP - 855

EP - 860

JO - Journal Francais d'Ophtalmologie

JF - Journal Francais d'Ophtalmologie

SN - 0181-5512

IS - 9

ER -